Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 5Hodgkin Disease 3Thrombocytopenia 2Multiple Myeloma 2Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hematologic Neoplasms 1

Interventions

fludarabine 8ibrutinib 7fludarabine phosphate 7Cyclophosphamide 6Busulfan 6Whole-Body Irradiation 4Tacrolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Methotrexate 3Mesna 3Lenalidomide 3Bone Marrow Transplantation 3Bendamustine Hydrochloride 3thymoglobulin 2pirtobrutinib 2blinatumomab 2Vincristine 2Patient Reported Outcome Measures 2Doxorubicin 2Biopsy 2Behavior Therapy 2venetoclax 1sargramostim 1romiplostim 1pegylated granulocyte colony-stimulating factor 1pegaspargase 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphoid × romiplostim × Lymphoid × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡